Under construction – not a live service
Sign in
Taking people in EgyptPhase 2

Pentoxifylline added to mesalamine for ulcerative colitis

Tests pentoxifylline with mesalamine in adults with ulcerative colitis, a long-lasting bowel inflammation.

Plain-language title generated from the registry record
Registry title: Pentoxifylline in Patients With Ulcerative Colitis

Key facts

Where
Al Fayyum, EgyptSee the site
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT07349472, who can take part

Where in Egypt

  • Fayoum UniversityAl Fayyum, EgyptTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ihab Elsayed Hassan
Trial code
NCT07349472
Record updated
15 April 2026
Original description
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.Read full original descriptionShow less

Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis

Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.

Inclusion: Age ≥ 18 years; Both male and female will be included; Negative pregnancy test and effective contraception; Mild and moderate UC patients.

Exclusion: Patients taking rectal or systemic steroids; Patients taking immunosuppressives or biological therapies; Addiction to alcohol and / or drugs; Colorectal cancer patients; Known allergy to the studied medications; Breast feeding; Significant liver and kidney function abnormalities; Diabetic patients; Patients with severe UC.

ClinicalTrials.gov NCT07349472